Correlation Between Body Mass Index and Immunotherapy Response in Advanced NSCLC.
Walid Shalata et al. · Cancers · 2025
Background
Immune checkpoint inhibitors (ICIs) have revolutionized the management of advanced non-small cell lung cancer (NSCLC).
Purpose
This study aims to evaluate the impact of BMI on treatment efficacy and survival outcomes in advanced NSCLC patients treated with first-line ICI therapy.
Methods
A retrospective study was conducted at a multi-center registry to evaluate the impact of baseline BMI on overall survival (OS) and progression-free survival (PFS) in patients with stage IV NSCLC who received first-line ICI therapies.
More results
Among 346 patients, 12.72% were underweight, 45.38% normal weight, 29.19% overweight, and 12.72% obese.
Overweight and obese patients were more likely to receive pembrolizumab ( p = 0.039) and less likely to undergo chemotherapy ( p = 0.012).
More results
No significant differences in median overall survival (OS, log-rank: p = 0.155) or progression-free survival (PFS, log-rank: p = 0.370) were observed across BMI categories.